IMC Chicago’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.52M Sell
16,900
-14,800
-47% -$7.82M ﹤0.01% 1760
2026
Q2
$17M Buy
31,700
+14,500
+84% +$7.43M ﹤0.01% 1167
2026
Q1
$9M Buy
17,200
+800
+5% +$382K ﹤0.01% 1358
2025
Q4
$9.6M Buy
+16,400
New +$8.38M ﹤0.01% 1262
2023
Q2
– Sell
-20,600
Closed -$4.99M – 1355
2023
Q1
$4.99M Sell
20,600
-25,600
-55% -$6.98M 0.01% 649
2022
Q4
$13.4M Buy
+46,200
New +$4.52M 0.02% 394

Other funds holding MDGL

IMC Chicago's MDGL Position: Q3 2026 in Review

IMC Chicago reduced its Madrigal Pharmaceuticals (MDGL) stake by 30% in Q3 2026, selling an estimated $1.72M and leaving 7,594 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

IMC Chicago first reported a position in MDGL in Q4 2025 and has held it in 4 quarters since. The position peaked at $7.02M in Q4 2025. 435 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • IMC Chicago held 7,594 shares of Madrigal Pharmaceuticals worth $3.83M as of Q3 2026.
  • IMC Chicago sold 3,253 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $1.72M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #2486 holding.
  • IMC Chicago first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • IMC Chicago's Madrigal Pharmaceuticals position peaked at $7.02M in Q4 2025.
  • 435 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.